Evidence map›Paper›PMID 24724600›Full record

ArticleArchives of Iranian medicine2014

Endoscopic screening for precancerous lesions of the esophagus in a high risk area in Northern Iran.

Gholamreza Roshandel, Masoud Khoshnia, Masoud Sotoudeh, Shahin Merat, Arash Etemadi, Arash Nickmanesh, Alireza Norouzi, Akram Pourshams, Hossein Poustchi, Shahryar Semnani and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Archives of Iranian medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02311712 (Non-endoscopic Esophageal Cancer Screening Program in Northern Iran), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02311712 nasuspendednot on this mapstarted 2016, after this paper: background citation

Non-endoscopic Esophageal Cancer Screening Program in Northern Iran

TypeinterventionalSponsorTehran University of Medical SciencesRan2016 to 2029Enrolled12,000ConditionsEsophageal CancerArmsCapsule sponge
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Gholamreza Roshandel1)Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2)Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.khoshniamd@gmail.com.
Masoud KhoshniaGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Masoud SotoudehDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Shahin MeratDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Arash Etemadi1)Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3)Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Arash NickmaneshDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Alireza NorouziGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Akram PourshamsDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hossein PoustchiDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Shahryar SemnaniGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Fatemeh Ghasemi-KebriaGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Roya NoorbakhshDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Christian AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Sanford M DawseyDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Reza MalekzadehDigestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Shariati Hospital · IRGolestan University · IRTehran University of Medical Sciences · IRDivision of Cancer Epidemiology and GeneticsGolestan University of Medical Sciences · IR

Funding

Upper Gastrointestinal Cancer StudiesZIACP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$25.6M
Intramural NIH HHS ZIA CP000185
6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) is a major health problem in many developing countries including Iran. ESCC has a very poor prognosis, largely due to late diagnosis. As a first step in developing an early detection and treatment program, we conducted a population-based endoscopic screening for ESCC and its precursor lesion, esophageal squamous dysplasia (ESD) in asymptomatic adults from Golestan Province, northern Iran, a high-risk area for ESCC, to evaluate the feasibility of such a program and to document the prevalence and risk factor correlates of ESD.

methodsThis cross-sectional study was conducted among participants of the Golestan Cohort Study (GCS), a population-based cohort of 50,000 adults in eastern Golestan Province. Randomly selected GCS participants were invited by telephone. Those who accepted were referred to a central endoscopy clinic. Eligible subjects were consented and then asked to fill in a brief questionnaire. Detailed information about selected risk factors was obtained from the GCS main database. Endoscopic examination with Lugol's iodine staining was performed, biopsies were taken from unstained lesions as well as the normally stained mucosa of the esophagus, and the biopsies were diagnosed by expert pathologists according to previously described criteria.

resultsIn total, 1906 GCS subjects were invited, of whom only 302 subjects (15.8%) were successfully enrolled. Esophagitis (29.5%) and ESD (6.0%) were the most common pathological diagnoses. Turkmen ethnicity (adjusted OR = 8.61; 95%CI: 2.48-29.83), being older than the median age (OR = 7.7; 95% CI: 1.99-29.87), and using deep frying cooking methods (OR = 4.65; 95%CI: 1.19-18.22) were the strongest predictors for ESD. There were significant relationships between esophagitis and smoking (p-value<0.001), drinking hot tea (P value = 0.02) and lack of education (P value = 0.004).

conclusionWe observed a low rate for participation in endoscopic screening. Overall prevalence of ESD was 6.0%. Developing non-endoscopic primary screening methods and screening individuals with one or more risk factors may improve these rates.

Indexed as

Early Detection of CancerAdultAgedAged, 80 and overAge FactorsBiopsyColoring AgentsCookingCross-Sectional StudiesEducational StatusEsophagitisEsophagoscopyEsophagusFemaleHumansIodidesColoring AgentsIodidesLugol's solutionTea

Identifiers

PMID24724600
PMCPMC5759310
OpenAlexW2148651112

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.